Select committee: Petitions Committee

Funding for research into brain tumours

Closed Opened 19 Oct 2015 Closed 19 Oct 2015
Inquiry scope (the committee's words)
The Petitions Committee publishes its report "Funding for research into brain tumours", revealing the distressing experiences of people whose lives have been affected by the disease, as well as exploring the reasons behind the historic underfunding of research under successive governments. Government response Read the Government response to funding for research into brain tumours Read the Government response to funding for research into brain tumours (PDF 209 KB) Following an e-petition, which was started on petition.parliament.uk and reached over 14,000 signatures, the Petitions Committee investigated the subject of funding for brain tumour research.

Where it stands

The inquiry is closed, opened 19 October 2015.

The committee has published 1 report, most recently Funding for research into brain tumours (1.22 MB) on 14 March 2016.

The government's response

Published 16 June 2016.

Summary written by Accountability Index from the government's response. It is not the government's own words.

The Government "accept[s] that action is needed" on brain tumour research and says there is "insufficient research being carried out", and it says it will address this by convening a working group.

  • On funding, the Government agrees that "an increase in the level of brain tumour research is crucial" and says it is "committed to work to achieve this in partnership" with charities, the NHS and industry.
  • The Minister for Life Sciences will be "convening a working group of clinicians, charities and officials" to discuss how to address the need for more brain tumour research. No date is stated in the document.
  • On early diagnosis, it says it has "committed to implementing recommendation 24": by 2020 everyone referred with suspected cancer will receive "either a definitive diagnosis or the all-clear within four weeks".
  • On NICE guidance, the Government says it is "for NICE as an independent body to decide what evidence should be considered" in reviewing its guidance. On non-therapeutic drugs, it says decisions are "for commissioners and providers, not for Government".

Read the government's response ↗ Report an error

Reports

1 report

Oral evidence sessions

2 sessions

On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.

Date Session and witnesses Source
24 Nov 2015
Oral evidence session
No witnesses recorded
View ↗
3 Nov 2015
Oral evidence session
No witnesses recorded
View ↗

Correspondence

1 letter

On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.

PublishedDirectionLetter
6 Sep 2016 To committee Letter from the Parliamentary Under Secretary for Life Sciences to the Chair